StockIQpro
NASDAQ:ONCY

Oncolytics Biotech Inc.

Track all markets on TradingView
Track all markets on TradingView

Oncolytics Biotech Inc. reported net income of −$28.8M in fiscal 2025. Free cash flow was −$20.1M, and the diluted share count rose 25.3%.Summary generated from Oncolytics Biotech Inc.'s SEC filings. Latest annual report filed Mar 30, 2026.

Key statistics

Fiscal 2025 from SEC filings. Methodology
Revenue (FY25)n/a
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equityn/a
Debt / equityn/a
Free cash flow−$20.1M
FCF marginn/a
Share count change+25.3%

Financials

Fiscal years, $M
Item20242025
Revenuen/an/a
Operating income−26−29
Net income−23−29
Free cash flow−20−20

Recent filings

From SEC EDGAR

Peers

Pharmaceutical preparations